Slingshot members are tracking this event:

European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion of Teva's (TEVA) Trisenox in Treatment of Promyelocytic Leukemia. Final Decision Expected in ~60 Days.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 21, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords European Medicines Agency, Chmp, Positive Opinion, Trisenox, First Line Treatment, Low- To Intermediate Risk, Acute Promyelocytic Leukemia (apl)